The United States has officially approved Gilead Sciences’ antimicrobial drug Remadacivir for use in hospitalized patients with Kovid-19 disease. The drug was officially approved by the US Food and Drug Administration (FDA) on Thursday (October 22) by the British news agency Reuters.
Following the FDA’s move, Kovid-19 is the first and only drug treatment approved for treatment in the United States. It is applied intravenously. The drug was used to treat US President Donald Trump’s corona.
However, the World Health Organization said last week that their global study did not find enough evidence for treatment in patients. However, the study has not yet been reviewed by external researchers. However, since last May, rescue has been used under emergency FDA approval. This time the drug was officially approved.
The guilds are not satisfied with research by the World Health Organization. He claims that there may be ‘bias’ in that study. Gilead said that they are currently meeting the demand for abatement in the United States. And by the end of October, they will be able to meet global demand. His medicine has received approval or provisional approval in about 50 countries around the world.